申请人:ELI LILLY AND COMPANY
公开号:EP0714891A1
公开(公告)日:1996-06-05
This invention provides a novel series substituted piperidines, pyrrolidines, and hexamethyleneimines which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds. The compounds have the formula
wherein:
p is 1, 2, or 3;
m and n are independently 0-6;
X is
N-Ra, or CH-NRbRc,
where Ra, Rb, and Rc are independently selected from the group consisting of hydrogen and C1-C6 alkyl;
R1 and R2 are independently hydrogen, halo, trifluoromethyl, trichloromethyl, C1-C6 alkyl, or C1-C6 alkoxy; and
R3, R4, and R5 are independently selected from the group consisting of hydrogen, halo, trifluoromethyl, C1-C6 alkyl, C1-C6 alkoxy, cyano, hydroxy, amino, -NHCONH2, nitro, -CONH2, C2-C10 alkenyl, C2-C10 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, C3-C8 cycloalkoxy, C1-C10 alkylthio, C1-C10 alkylamino, C2-C6 alkanoyl, and C2-C6 alkanoyloxy;
or a pharmaceutically acceptable salt or solvate thereof.
本发明提供了一系列新型的取代哌啶、吡咯烷和六亚甲基亚胺,它们可用于治疗或预防与速激肽过量有关的生理紊乱。本发明还提供了治疗此类生理紊乱的方法以及采用这些新型化合物的药物制剂。这些化合物的化学式为
其中
p 是 1、2 或 3;
m 和 n 独立地为 0-6
X 是
N-Ra,或 CH-NRbRc、
其中 Ra、Rb 和 Rc 独立地选自氢和 C1-C6 烷基组成的组;
R1 和 R2 独立地为氢、卤代、三氟甲基、三氯甲基、C1-C6 烷基或 C1-C6 烷氧基;以及
R3、R4 和 R5 独立选自由氢、卤素、三氟甲基、C1-C6 烷基、C1-C6 烷氧基、氰基、羟基、氨基、-NHCONH2、硝基、-CONH2、C2-C10 烯基、C2-C10 炔基、C3-C8 环烷基、C3-C8 环烯基、C3-C8 环烷氧基、C1-C10 烷硫基、C1-C10 烷基氨基、C2-C6 烷酰基和 C2-C6 烷酰氧基组成的组;
或其药学上可接受的盐或溶液。